Dr. Selick has served on our board of directors since February 2009. He is currently Chief Executive Officer and board member of Hinge Bio, Inc., a private biotechnology company focused on developing therapeutics for patients living with cancer. He previously served as Vice Chancellor of Business Development, Innovation and Partnerships at the University of California, San Francisco, from April 2017 to December 2022. Dr. Selick was a Venture Partner at Mission Bay Capital, a venture capital firm, from 2018 until his resignation at the end of 2022. Previously, he was the Chief Executive Officer of Threshold Pharmaceuticals, Inc., a biotechnology company, from June 2002 until the company’s merger with Molecular Templates Inc. in April 2017. From June 2002 until July 2007, Dr. Selick was also a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company, which was acquired two years after its founding. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. Dr. Selick serves as Chairman of the board of directors of Molecular Templates, Inc. (Nasdaq: MTEM), a biopharmaceutical company. Dr. Selick previously served as Lead Director and then Chairman of PDL BioPharma, Inc., a biopharmaceutical company, from 2009 to December 2019, and served as Chairman of the board of directors of Threshold Pharmaceuticals, Inc. until it merged with Molecular Templates Inc. in April 2017. Dr. Selick received a B.A. in Biophysics and a Ph.D. in Biology from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.
What is Harold E. Selick's net worth?
The estimated net worth of Harold E. Selick is at least $6.43 million as of March 26th, 2026. Selick owns 60,845 shares of Protagonist Therapeutics stock worth more than $6,432,168 as of March 31st. This net worth estimate does not reflect any other investments that Selick may own. Learn More about Harold E. Selick's net worth.
How do I contact Harold E. Selick?
Has Harold E. Selick been buying or selling shares of Protagonist Therapeutics?
During the last quarter, Harold E. Selick has sold $2,520,000.00 of Protagonist Therapeutics stock. Most recently, Harold E. Selick sold 24,000 shares of the business's stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $105.00, for a transaction totalling $2,520,000.00. Following the completion of the sale, the director now directly owns 60,845 shares of the company's stock, valued at $6,388,725. Learn More on Harold E. Selick's trading history.
Who are Protagonist Therapeutics' active insiders?
Are insiders buying or selling shares of Protagonist Therapeutics?
In the last year, insiders at the sold shares 25 times. They sold a total of 416,247 shares worth more than $34,662,346.57. The most recent insider tranaction occured on March, 26th when insider Arturo Md Molina sold 15,000 shares worth more than $1,571,850.00. Insiders at Protagonist Therapeutics own 4.9% of the company.
Learn More about insider trades at Protagonist Therapeutics. Information on this page was last updated on 3/26/2026.
